Advertisement

Topics

Latest "Indiana Blood Marrow Transplantation" News Stories

19:45 EDT 22nd October 2018 | BioPortfolio

Here are the most relevant search results for "Indiana Blood Marrow Transplantation" found in our extensive news archives from over 250 global news sources.

More Information about Indiana Blood Marrow Transplantation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Indiana Blood Marrow Transplantation for you to read. Along with our medical data and news we also list Indiana Blood Marrow Transplantation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Indiana Blood Marrow Transplantation Companies for you to search.

Showing "Indiana Blood Marrow Transplantation" News Articles 1–25 of 6,000+

Extremely Relevant

Elevated Late Mortality Persists After Blood or Marrow Transplant

WEDNESDAY, Aug. 8, 2018 -- Individuals who underwent allogeneic blood or marrow transplantation (BMT) in childhood have elevated risk of late mortality 25 years or more after transplantation, according to a study published online July 26 in JAMA...


Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2

Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation


Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

Researchers engineer human bone marrow tissue

Every day in the bone marrow several billion blood cells are formed. This constant supply is ensured by blood stem cells located in special niches within the marrow. These stem cells can multiply and mature into red and white blood cells, which then leave the bone marrow and enter the bloodstream. F...

Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpla

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Reviewers

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Working Parties

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Oral Session

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: STATISTICAL SYMPOSIUM - POSTER SESSION

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: QUALITY MANAGEMENT GROUP — POSTER SESSION

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group—Poster Session

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: QUALITY MANAGEMENT GROUP — ORAL SESSION

Solution to medical mystery may help some children avoid bone marrow transplantation

(St. Jude Children's Research Hospital) Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder. The answer may allow some children to avoid the risk and expense of bone marrow transplantation, a common treatment for leukemia and bone marrow disorders. Investigators at St. Jude Children's Research Hospital and UCSF, led the st...

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

NEW YORK, June 19, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that data from a Phase 1 clinical trial evaluating Fortress’ CNDO-109-activated allogeneic natural killer (NK) cells in acute myeloid leukemia (AML) patie...

Relevant

Research identifies link between rare gene variants and survival after blood and marrow transplant

Blood and marrow transplant, or BMT, is a lifesaving and effective treatment for many patients, but the procedure can cause serious and life-threatening complications.

A new vulnerability in targeting blood cancer

AML is not a single disease. It is a group of leukemias that develop in the bone marrow from progenitors of specialized blood cells, the so-called myeloid cells. Rapidly growing and dividing, these aberrant cells crowd the bone marrow and bloodstream,...

Answer to decades-old mystery may allow some children to avoid bone marrow transplantation

Researchers have helped solve a decades-old mystery about which mutations are responsible for an inherited bone marrow disorder.

NYU Langone's Perlmutter Cancer Center expands Blood and Marrow Transplant Program

To further advance the study and treatment of blood cancers, Perlmutter Cancer Center at NYU Langone Health has significantly expanded its Blood and Marrow Transplant Program.

Vascugen licenses tech for blood vessel regeneration developed at IU School of Medicine

(Indiana University) Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury.

Patients who underwent blood, marrow transplants may be at high risk of premature death

While blood and marrow transplants can save the life of a pediatric cancer patient, research out of the University of Alabama at Birmingham found that those patients may be at an increased risk of premature death even years or decades after the procedure as compared with the general population.

Introducing Prof. Shaun McCann, Bone Marrow Transplantation’s New Sommelier

New light shed on how bone marrow niches keep stem cells thriving

(Osaka University) Hematopoietic stem cells (HSCs) require specialized niches in bone marrow to generate functional blood cells. CAR cells are among cell types located in niches, but their function is poorly understood. Researchers identified a protein, Ebf3, in CAR cells that is needed to maintain the bone marrow cavities and the HSC niche. With no Ebf3, HSC abundance is greatly reduced, and bone...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks